PL1888031T3 - Preparaty analogu glp-1 - Google Patents
Preparaty analogu glp-1Info
- Publication number
- PL1888031T3 PL1888031T3 PL06744133T PL06744133T PL1888031T3 PL 1888031 T3 PL1888031 T3 PL 1888031T3 PL 06744133 T PL06744133 T PL 06744133T PL 06744133 T PL06744133 T PL 06744133T PL 1888031 T3 PL1888031 T3 PL 1888031T3
- Authority
- PL
- Poland
- Prior art keywords
- glp
- analogue formulations
- analogue
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2005/002217 WO2005117830A1 (en) | 2004-06-04 | 2005-06-06 | Liquid depot formulations |
| PCT/GB2005/004752 WO2006075125A1 (en) | 2005-01-14 | 2005-12-09 | GnRH ANALOGUE FORMULATIONS |
| EP06744133A EP1888031B1 (en) | 2005-06-06 | 2006-06-06 | Glp-1 analogue formulations |
| PCT/GB2006/002079 WO2006131730A1 (en) | 2005-06-06 | 2006-06-06 | Glp-1 analogue formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1888031T3 true PL1888031T3 (pl) | 2013-04-30 |
Family
ID=36741345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06744133T PL1888031T3 (pl) | 2005-06-06 | 2006-06-06 | Preparaty analogu glp-1 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8546326B2 (pl) |
| EP (1) | EP1888031B1 (pl) |
| JP (1) | JP5198261B2 (pl) |
| CN (1) | CN101217940B (pl) |
| CA (1) | CA2609810C (pl) |
| DK (1) | DK1888031T3 (pl) |
| ES (1) | ES2399645T3 (pl) |
| PL (1) | PL1888031T3 (pl) |
| WO (1) | WO2006131730A1 (pl) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ551990A (en) * | 2004-06-04 | 2011-01-28 | Camurus Ab | Liquid depot formulations |
| ATE501710T1 (de) | 2005-01-14 | 2011-04-15 | Camurus Ab | Somatostatin-analog-formulierungen |
| ES2458992T3 (es) | 2005-01-14 | 2014-05-07 | Camurus Ab | Formulaciones de análogos de GnRH |
| US9649382B2 (en) | 2005-01-14 | 2017-05-16 | Camurus Ab | Topical bioadhesive formulations |
| NZ560568A (en) | 2005-01-21 | 2011-02-25 | Camurus Ab | Particulate compositions comprising phosphatidyl choline, diacyl glycerol or tocopherol, and a non-ionic stabilising amphiphile |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| US8546326B2 (en) | 2005-06-06 | 2013-10-01 | Camurus Ab | Glp-1 analogue formulations |
| SI1965823T1 (sl) | 2005-11-04 | 2016-09-30 | Glaxosmithkline Llc Corporation Service Company | Postopki za dajanje hipoglikemičnih sredstev |
| ES2398126T3 (es) | 2006-08-09 | 2013-03-13 | Intarcia Therapeutics, Inc | Sistemas de liberación osmótica y unidades de pistón |
| US20080234376A1 (en) * | 2007-03-21 | 2008-09-25 | Taiwan Liposome Company (A Taiwan Corporation) | Emulsion composition comprising prostaglandin e1 |
| CN105688191A (zh) * | 2007-04-23 | 2016-06-22 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
| GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| EP2052716B1 (en) * | 2007-10-24 | 2014-12-31 | Camurus AB | Controlled release formulations |
| US8343140B2 (en) | 2008-02-13 | 2013-01-01 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| GB0815435D0 (en) * | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| SG10201703039SA (en) * | 2008-09-04 | 2017-05-30 | Amylin Pharmaceuticals Llc | Sustained release formulations using non-aqueous carriers |
| PL3228320T3 (pl) | 2008-10-17 | 2020-06-01 | Sanofi-Aventis Deutschland Gmbh | Kombinacja insuliny i agonisty GLP-1 |
| US20100183876A1 (en) * | 2008-12-23 | 2010-07-22 | Hell Andre | Process for the Preparation of a Peptide Powder Form |
| EP2445544A1 (en) * | 2009-06-25 | 2012-05-02 | Sanofi-Aventis Deutschland GmbH | Cannula assembly for co-delivery of medicaments |
| LT2462246T (lt) | 2009-09-28 | 2017-11-27 | Intarcia Therapeutics, Inc | Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas |
| WO2011056713A2 (en) * | 2009-11-03 | 2011-05-12 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist compounds for obstructive sleep apnea |
| DK2498801T3 (en) | 2009-11-13 | 2018-05-07 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION INCLUDING desPro36Exendin-4 (1-39) -Lys6-NH2 AND METHIONIN |
| SI2554183T1 (en) | 2009-11-13 | 2018-08-31 | Sanofi-Aventis Deutschland Gmbh | A pharmaceutical composition comprising the GLP-1 agonist and insulin and methionine |
| US8314080B2 (en) | 2010-04-06 | 2012-11-20 | Kuwait University | Method of treating type I diabetes |
| KR101823320B1 (ko) | 2010-08-30 | 2018-01-31 | 사노피-아벤티스 도이칠란트 게엠베하 | 제２형 진성 당뇨병 치료용 약제를 제조하기 위한 ａｖｅ００１０의 용도 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| CA2836847C (en) * | 2011-05-25 | 2021-06-29 | Camurus Ab | Controlled release peptide formulations |
| WO2012160212A1 (en) | 2011-05-25 | 2012-11-29 | Camurus Ab | Peptide controlled-release formulations |
| DK2750699T3 (en) | 2011-08-29 | 2015-10-26 | Sanofi Aventis Deutschland | A pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| DE102011114986A1 (de) * | 2011-09-28 | 2013-03-28 | Ethris Gmbh | Sprühsystem |
| PE20141297A1 (es) | 2011-12-05 | 2014-10-09 | Camurus Ab | Formulaciones peptidicas robustas de liberacion controlada |
| KR20150000874A (ko) | 2012-01-31 | 2015-01-05 | 산텐 세이야꾸 가부시키가이샤 | 비수성 액체 조성물 |
| WO2013172954A1 (en) | 2012-05-17 | 2013-11-21 | Ra Pharmaceuticals, Inc | Peptide and peptidomimetic inhibitors |
| NZ702028A (en) * | 2012-05-25 | 2016-07-29 | Camurus Ab | Somatostatin receptor agonist formulations |
| MY189481A (en) | 2012-07-26 | 2022-02-16 | Camurus Ab | Opioid formulations |
| US9937164B2 (en) | 2012-07-26 | 2018-04-10 | Camurus Ab | Opioid formulations |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| MA38276B1 (fr) | 2012-12-21 | 2018-03-30 | Sanofi Sa | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015104314A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| KR20160104726A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형 |
| CA2932873A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| JP6568102B2 (ja) | 2014-04-28 | 2019-08-28 | オーフォームド，インコーポレイティド | ブプレノルフィン二量体及び消化管疾患の治療におけるその使用 |
| HRP20211561T8 (hr) | 2014-06-12 | 2022-03-04 | Ra Pharmaceuticals, Inc. | Modulacija aktivnosti komplementa |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| TN2017000235A1 (en) | 2014-12-12 | 2018-10-19 | Sanofi Aventis Deutschland | Insulin glargine/lixisenatide fixed ratio formulation |
| PL3250230T3 (pl) | 2015-01-28 | 2022-02-14 | Ra Pharmaceuticals, Inc. | Modulatory aktywności dopełniacza |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| AU2016267052B2 (en) | 2015-05-22 | 2022-01-20 | The Bot Of The Leland Stanford Junior University | Treatment of post-bariatric hypoglycemia with GLP-1 antagonists |
| RU2730996C2 (ru) | 2015-06-03 | 2020-08-26 | Интарсия Терапьютикс, Инк. | Системы установки и извлечения имплантата |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| LT3685847T (lt) | 2015-12-16 | 2023-03-27 | Ra Pharmaceuticals, Inc. | Komplemento aktyvumo moduliatoriai |
| WO2017152014A1 (en) | 2016-03-04 | 2017-09-08 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
| US20190105268A1 (en) * | 2016-03-31 | 2019-04-11 | Sun Pharma Advanced Research Company Limited | Viscoelastic Gel of Liraglutide Adapted for Once-Weekly or Once Bi-Weekly Administration |
| WO2017181061A1 (en) | 2016-04-15 | 2017-10-19 | Ra Pharmaceuticals, Inc. | Ras binding peptides and methods of use |
| KR102574993B1 (ko) | 2016-05-16 | 2023-09-06 | 인타르시아 세라퓨틱스 인코포레이티드 | 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법 |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| IL265270B (en) | 2016-09-15 | 2022-09-01 | Camurus Ab | Prostacyclin analog formulations |
| JP7138626B2 (ja) * | 2016-09-27 | 2022-09-16 | カムルス エービー | アルキルアンモニウムｅｄｔａ塩を含む混合物及び製剤 |
| EP3541366B1 (en) | 2016-11-21 | 2024-12-25 | Amylyx Pharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
| CA3045114A1 (en) | 2016-12-07 | 2018-06-14 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| CN108606957A (zh) * | 2016-12-13 | 2018-10-02 | 南京星银药业集团有限公司 | 一种含索马鲁肽的口服缓释制剂及其制备方法 |
| CA3049034A1 (en) | 2017-01-03 | 2018-07-12 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug |
| EA202192919A1 (ru) | 2019-05-29 | 2022-02-18 | Камурус Аб | Композиции на основе липидов с контролируемым высвобождением |
| EP3842449A1 (en) * | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled olefin co-agonists of the glucagon and glp-1 receptors |
| EP3842061A1 (en) * | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled triazole co-agonists of the glucagon and glp-1 receptors |
| WO2025229402A1 (en) * | 2024-05-02 | 2025-11-06 | Camurus Ab | Lipid compositions and methods of use thereof |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5340802A (en) | 1989-06-30 | 1994-08-23 | Abbott Laboratories | Peptide analog type-B CCK receptor ligands |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| US5531925A (en) | 1991-10-04 | 1996-07-02 | Gs Biochem Ab | Particles, method of preparing said particles and uses thereof |
| WO1993006921A1 (en) | 1991-10-04 | 1993-04-15 | Gs Biochem Ab | Particles, method of preparing said particles and uses thereof |
| US6228383B1 (en) | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
| DE69510190T2 (de) | 1994-03-30 | 2000-01-27 | Gs Dev Ab | Verwendung von fettsäureester als bioklebstoffe |
| SE518578C2 (sv) | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
| FR2725369B1 (fr) | 1994-10-07 | 1997-01-03 | Oreal | Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire |
| JPH11513393A (ja) | 1995-10-12 | 1999-11-16 | ジーエス ディベロップメント エービー | 皮膚又は粘膜表面へのもしくは介する活性物質の投与用医薬組成物 |
| US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| PT839525E (pt) * | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
| JP2001524958A (ja) | 1997-04-17 | 2001-12-04 | ジーエス ディベロップメント アクティエボラーグ | 新規な液晶をベースとする生物接着性薬剤送出系 |
| US6638621B2 (en) | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
| US20040018241A1 (en) | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| SI1140148T1 (sl) | 1998-12-22 | 2006-04-30 | Lilly Co Eli | Stabilna formulacija raztopine glukagonu podobnega peptida-1 |
| US6467987B1 (en) * | 1999-03-29 | 2002-10-22 | Honeywell International Inc. | Resettable non-explosive actuator |
| US20020153508A1 (en) | 2000-06-29 | 2002-10-24 | Lynch Matthew Lawrence | Cubic liquid crystalline compositions and methods for their preparation |
| US7008646B2 (en) | 2001-02-20 | 2006-03-07 | Patrick Thomas Spicer | Cubic liquid crystalline compositions and methods for their preparation |
| US6936187B2 (en) | 2001-02-21 | 2005-08-30 | Matthew Lawrence Lynch | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| US6656385B2 (en) | 2001-02-21 | 2003-12-02 | The Procter & Gamble Company | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| US6991809B2 (en) | 2001-06-23 | 2006-01-31 | Lyotropic Therapeutics, Inc. | Particles with improved solubilization capacity |
| JP5562510B2 (ja) | 2001-06-28 | 2014-07-30 | ノヴォ ノルディスク アー／エス | 修飾ｇｌｐ−１の安定な処方剤 |
| WO2003057235A2 (en) * | 2002-01-10 | 2003-07-17 | Imperial College Innovations Ltd | Modification of feeding behavior |
| US7622118B2 (en) | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| GB0305941D0 (en) | 2003-03-14 | 2003-04-23 | Camurus Ab | Composition |
| GB0307777D0 (en) | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
| WO2005014163A1 (en) | 2003-08-04 | 2005-02-17 | Camurus Ab | Method for loading amphiphile particles with active agents |
| EP1663295A2 (en) * | 2003-09-01 | 2006-06-07 | Novo Nordisk A/S | Stable formulations of peptides |
| GB0322033D0 (en) | 2003-09-19 | 2003-10-22 | Camurus Ab | Composition |
| BR122019021416A2 (pl) * | 2003-09-19 | 2019-12-21 | ||
| GB0325745D0 (en) * | 2003-11-05 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
| US8865021B2 (en) | 2003-11-07 | 2014-10-21 | Camurus Ab | Compositions of lipids and cationic peptides |
| WO2005063213A1 (en) | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Rigid liposomal cochleate and methods of use and manufacture |
| EP1713446B1 (en) | 2004-01-23 | 2010-12-01 | Camurus Ab | Ternary non-lamellar lipid compositions |
| GB0401513D0 (en) | 2004-01-23 | 2004-02-25 | Camurus Ab | Compositions |
| NZ551990A (en) | 2004-06-04 | 2011-01-28 | Camurus Ab | Liquid depot formulations |
| KR101234885B1 (ko) | 2004-08-04 | 2013-02-19 | 카무러스 에이비 | 비층상 분산을 형성하는 조성물 |
| ATE501710T1 (de) | 2005-01-14 | 2011-04-15 | Camurus Ab | Somatostatin-analog-formulierungen |
| EP1845942B1 (en) | 2005-01-14 | 2014-04-09 | Camurus Ab | Gnrh analogue formulations |
| ES2458992T3 (es) | 2005-01-14 | 2014-05-07 | Camurus Ab | Formulaciones de análogos de GnRH |
| EP1843746B1 (en) | 2005-01-14 | 2011-03-16 | Camurus Ab | Somatostatin analogue formulations |
| NZ560568A (en) | 2005-01-21 | 2011-02-25 | Camurus Ab | Particulate compositions comprising phosphatidyl choline, diacyl glycerol or tocopherol, and a non-ionic stabilising amphiphile |
| US8546326B2 (en) | 2005-06-06 | 2013-10-01 | Camurus Ab | Glp-1 analogue formulations |
| ES2437581T3 (es) | 2005-11-17 | 2014-01-13 | Zogenix, Inc. | Suministro de formulaciones viscosas por inyección sin aguja |
| GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
-
2006
- 2006-06-06 US US11/908,740 patent/US8546326B2/en active Active
- 2006-06-06 WO PCT/GB2006/002079 patent/WO2006131730A1/en not_active Ceased
- 2006-06-06 EP EP06744133A patent/EP1888031B1/en active Active
- 2006-06-06 CN CN2006800244885A patent/CN101217940B/zh active Active
- 2006-06-06 ES ES06744133T patent/ES2399645T3/es active Active
- 2006-06-06 CA CA2609810A patent/CA2609810C/en active Active
- 2006-06-06 PL PL06744133T patent/PL1888031T3/pl unknown
- 2006-06-06 DK DK06744133.7T patent/DK1888031T3/da active
- 2006-06-06 JP JP2008515284A patent/JP5198261B2/ja active Active
-
2007
- 2007-10-24 US US11/877,935 patent/US8097239B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008542437A (ja) | 2008-11-27 |
| US8546326B2 (en) | 2013-10-01 |
| US8097239B2 (en) | 2012-01-17 |
| CA2609810C (en) | 2012-05-22 |
| CA2609810A1 (en) | 2006-12-14 |
| CN101217940B (zh) | 2013-03-27 |
| ES2399645T3 (es) | 2013-04-02 |
| DK1888031T3 (da) | 2013-02-18 |
| EP1888031B1 (en) | 2013-01-23 |
| CN101217940A (zh) | 2008-07-09 |
| EP1888031A1 (en) | 2008-02-20 |
| JP5198261B2 (ja) | 2013-05-15 |
| US20080146490A1 (en) | 2008-06-19 |
| WO2006131730A1 (en) | 2006-12-14 |
| US20080124394A1 (en) | 2008-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1888031T3 (pl) | Preparaty analogu glp-1 | |
| GB2424581B (en) | Formulations | |
| PL1845942T3 (pl) | Preparaty analogu GnRH | |
| ZA200708634B (en) | Novel vaccine formulations | |
| IL192104A0 (en) | Stable protein formulations | |
| PL1843746T3 (pl) | Formulacje analogów somatostatyny | |
| ZA200707654B (en) | Formulations | |
| EP1909584A4 (en) | PRENYLFLAVONOID FORMULATIONS | |
| IL192149A0 (en) | Stable s-nitrosothiol formulations | |
| EP1951693A4 (en) | SOLID FORMULATIONS | |
| GB0501809D0 (en) | Anti-migraine formulations | |
| EP1904525A4 (en) | GLP-1 PHARMACEUTICAL COMPOSITIONS | |
| IL179208A0 (en) | Intereferon formulations | |
| GB0523634D0 (en) | Solid cleaning formulations | |
| GB0520388D0 (en) | Formulations | |
| GB0526322D0 (en) | Formulations | |
| GB0522917D0 (en) | Formulations | |
| GB0518878D0 (en) | Formulations | |
| GB0500917D0 (en) | Novel formulations | |
| GB0522828D0 (en) | Novel formulations | |
| GB0500912D0 (en) | Novel formulations | |
| GB0504106D0 (en) | Novel formulations | |
| GB0500915D0 (en) | Novel formulations | |
| GB0500913D0 (en) | Novel formulations | |
| GB0519090D0 (en) | Novel formulations |